NCT05197062View on ClinicalTrials.gov

A Study of 14C JNJ-67953964 in Healthy Adult Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

March 2, 2022

Study Completion Date

March 2, 2022

Conditions

Healthy

Interventions

DRUG

14C-aticaprant

14C-aticaprant will be administered orally as capsule on Day 1.

Trial Locations (1)

NZ 9728

PRA Health Sciences, Groningen

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY